Evidence map›Paper›PMID 19647308›Full record

ArticleGynecologic oncology2009

Retracted: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Douglas D Taylor, Cicek Gercel-Taylor, Lynn P Parker

RetractedOpen access · greenAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 85 citations in OpenAlex.

  1. Ascites analysis by a microfluidic chip allows tumor-cell profiling.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Trial
  2. Article
  3. Review
  4. Article
  5. Immune Tumor Microenvironment in Ovarian Cancer Ascites.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. MUC16 as a novel target for cancer therapy.Expert opinion on therapeutic targets · 2018
    Review
  11. Review
  12. Article
  13. Article
  14. [Progress and analysis methods of clinical application of extracellular vesicles].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Douglas D TaylorDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, KY 40292, USA. Electronic address: ddtaylor@louisville.edu.
Cicek Gercel-TaylorDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, KY 40292, USA.
Lynn P ParkerDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, KY 40292, USA.
University of Louisville · US

Funding

Tumor-reactive IgG in the diagnosis of ovarian cancerR21CA098166 · NCI · UNIVERSITY OF LOUISVILLE · PI TAYLOR, DOUGLAS DILLON · 2004 to 2005
$264k
NCI NIH HHS R21 CA098166
6 · The paper itself

Abstract

objectiveMost ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.

methodsThe diagnostic array utilizes specific exosome-derived antigens to detect reactive IgG in patients' sera. Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines. Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer. Immunoreactivity was also compared between exosomal proteins and their recombinant counterparts.

resultsSera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested). Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease. Reactivity with placental type alkaline phosphatase, TAG 72, survivin, NY-ESO-1, GRP78, and Muc16 (CA125) allowed the differentiation between Stage III/IV and early stage ovarian cancer.

conclusionsThe quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer. The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers. Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

Indexed as

AdultAntigens, NeoplasmAutoantibodiesBiomarkers, TumorCase-Control StudiesEndoplasmic Reticulum Chaperone BiPEpitopesExosomesFemaleHumansImmunoglobulin GMiddle AgedNeoplasm StagingOvarian NeoplasmsAntigens, NeoplasmAutoantibodiesBiomarkers, TumorEndoplasmic Reticulum Chaperone BiPEpitopesHSPA5 protein, humanImmunoglobulin G

Identifiers

PMID19647308
PMCPMC2760307
OpenAlexW2066872622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.